NEW YORK (GenomeWeb News) – Synthetic Genomics today announced today the launch of its wholly owned subsidiary SGI-DNA, and with Integrated DNA Technologies announced a deal between SGI-DNA and IDT to expand an existing collaboration.
SGI-DNA, based in La Jolla, Calif., will be responsible for all aspects of developing, manufacturing, and commercializing Synthetic Genomics' synthetic DNA technology. Fernanda Gandara is general manager of SGI-DNA and will continue as senior vice president of business development for Synthetic Genomics.
SGI-DNA's deal with IDT builds on a relationship forged a year ago by Synthetic Genomics and IDT to co-manufacture and co-brand cloned synthetic gene products up to 5 kb. IDT at the time also launched its gBlocks Gene Fragments product line.
Today's deal is to manufacture and co-brand cloned synthetic DNA constructs up to 2 Mbp, which SGI-DNA and IDT said is a product offering that had never before been available.
The products will "enable new applications including metabolic and whole-genome engineering through de novo synthesis," the partners said. SGI-DNA will manufacture the products and make them available through IDT. It is now IDT's exclusive supplier of larger DNA constructs, they said.
SGI-DNA and IDT will also collaborate on the launch of IDT's expanded gBlocks Gene
Fragment products later this year.
Financial and other terms of the deal were not disclosed.
In a statement, IDT Founder and CEO Joseph Walder said, "Through this strengthened collaboration, SGI-DNA and IDT will enable the research community by providing a complete solution, from short genes to very large synthetic constructs, at prices and with delivery times simply unavailable in the market today."
Based in Coralville, Iowa, IDT supplied custom nucleic acids.